



PARABOLIC DRUGS LTD.

(An ISO 14001 - 2004 Certified Company)



Ref. PDL: SCY: AUG: 2011-2012/

Dated: 13th August, 2011

The National Stock Exchange of India Limited,
"Exchange Plaza"
Bandra-Kurla Complex,
Bandra (East),
Mumbai (Maharashtra)

Subject: Press Release

Dear Sir,

Please find enclosed herewith press release with respect to performance of the Company for the quarter ended 30th June, 2011.

You are requested to kindly display the same on the Notice Board of your exchange for the information of members and general Public.

Thanking you,

Yours faithfully,
For Parabolic Drugs Limited,

Authorised Signatory

Enclosed: As Above.

Regd. Office : S.C.O. 99 - 100, 3rd & 4th Floor, Sector 17 - B,
Chandigarh - 160 017 (India)
Tel. : +91-172-3914646, 3914647 **Fax :** +91-172-3914645

Corp. Office : 9 AB, Taimoor Nagar, New Friends Colony,
New Delhi (India)
Tel. : +91-11-64510543, 26332660

Works - I : Village Sundhran, P.O. Mubarakpur, Derabassi (Pb.) India
Telefax : (01762) 280305

Works - II : 45, Industrial Area, Phase II, Panchkula (Hry.) India
Tel. : +91-172-2591443

R & D Centre : 280-281, HSIIDC, Tehsil Barwala,
District Panchkula (Hry.) India **Tel. :** +91-1733-256380

website : www.parabolicdrugs.com



PARABOLIC DRUGS LTD.

(An ISO 14001 - 2004 Certified Company)



Q1FY12 Performance


- The Company's sales increased by 46.61% to Rs. 205.47 Crores as compared to Rs. 140.15 Crores in Q1 FY 11
- Net profit increased by 44.19% to Rs. 15.18 Crores as compared to Rs. 10.53 Crores in Q1 FY 11
- EBITDA increased by 62.41% to Rs. 41.80 Crores as compared to Rs. 25.74 Crore in Q1 FY 11
- The Company's EBITDA margin was up 226 basis points to 22.45% on account of manufacturing efficiencies and technology enhancement
- The Company's net profit margin stood at 8.15% in Q1 FY12

FY11 Performance

- Net sales increased by 19.87% to Rs. 616.02 Crores during FY11 as compared to Rs. 513.89 Crores in FY10
- Net profit up 54.60% at Rs. 52.87 Crores as compared to Rs. 34.20 Crores in FY10
- EBITDA increased by 25.02% to Rs. 127.15 Crores in FY 11.
- The Board of Directors has recommended dividend at Re 0.50 per share on fully paid up equity shares of the company for the year 2010-11.

Major operational highlights for Q1

The company has taken a step towards its vision of becoming a complete vertically integrated Pharma company by entering the domestic formulations space. In the APIs, the company has successfully triggered the process of getting regulatory approvals from the Japanese markets for its Cephalosporin range of products. With this, the company is looking forward to penetrate into the world's second largest pharmaceutical market. The Company has also filed one drug master file for its first non-antibiotic molecule to USFDA; One Certificate of Suitability with EDQM for its Cephalosporin molecule. It also filed 1 process patents with Indian Patents Office, New Delhi. Now, the total regulatory filing strength stands at 37 Drug Master Files and 16 Process Patents.



Regd. Office : S.C.O. 99 - 100, 3rd & 4th Floor, Sector 17 - B,
Chandigarh - 160 017 (India)
Tel. : +91-172-3914646, 3914647 **Fax :** +91-172-3914645

Corp. Office : 9 AB, Taimoor Nagar, New Friends Colony,
New Delhi (India)
Tel. : +91-11-64510543, 26332660

Works - I : Village Sundhran, P.O. Mubarakpur, Derabassi (Pb.) India
Telefax : (01762) 280305

Works - II : 45, Industrial Area, Phase II, Panchkula (Hry.) India
Tel. : +91-172-2591443

R & D Centre : 280-281, HSIIDC, Tehsil Barwala,
District Panchkula (Hry.) India **Tel. :** +91-1733-256380

website : www.parabolicdrugs.com